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rognosis of “Masked” Hypertension
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y 24-h Ambulatory Blood Pressure Monitoring
0-Year Follow-Up From the Ohasama Study
akayoshi Ohkubo, MD, PHD,*§ Masahiro Kikuya, MD, PHD,*§ Hirohito Metoki, MD,†§
ei Asayama, MD,†§ Taku Obara, MS,†§ Junichiro Hashimoto, MD, PHD,*§
azuhito Totsune, MD, PHD,†§ Haruhisa Hoshi, MD, PHD,¶ Hiroshi Satoh, MD, PHD,‡§
utaka Imai, MD, PHD†§
endai and Iwate, Japan
OBJECTIVES We sought to investigate the prognosis in subjects with “white-coat” hypertension (WCHT)
and “masked” hypertension (MHT), in which blood pressure (BP) is lower in clinical
measurements than during ambulatory monitoring.
BACKGROUND The prognostic significance of WCHT remains controversial, and little is known about MHT.
METHODS We obtained 24-h ambulatory BP and “casual” BP (i.e., obtained in clinical scenarios) values
from 1,332 subjects (872 women, 460 men) 40 years old in a representative sample of the
general population of a Japanese community. Survival and stroke morbidity were then
followed up for a mean duration of 10 years.
RESULTS Composite risk of cardiovascular mortality and stroke morbidity examined using a Cox
proportional hazards regression model for subjects with WCHT (casual BP 140/90 mm
Hg, daytime BP135/85 mm Hg; relative hazards [RH])1.28; 95% confidence interval [CI]
0.76 to 2.14) was no different from risk for subjects with sustained normal BP (casual BP
140/90 mm Hg, daytime BP 135/85 mm Hg). However, risk was significantly higher for
subjects with MHT (casual BP 140/90 mm Hg, daytime BP 135/85 mm Hg; RH 2.13;
95% CI 1.38 to 3.29) or sustained hypertension (casual BP 140/90 mm Hg, daytime BP
135/85 mm Hg; RH 2.26; 95% CI 1.49 to 3.41) than for subjects with sustained normal
BP. Similar findings were observed for cardiovascular mortality and stroke morbidity among
subgroups by gender, use of antihypertensive medication, and risk factor level (all p for
heterogeneity 0.2).
CONCLUSIONS Conventional BP measurements may not identify some individuals at high or low risk, but
these people may be identifiable by the use of ambulatory BP. (J Am Coll Cardiol 2005;46:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.070508–15) © 2005 by the American College of Cardiology Foundation
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vhe utility of ambulatory blood pressure (BP) monitoring
as been recognized, and the practice has been adopted
See page 516
idely (1,2). This method of measuring BP evaluates BP
uring the daily life of the patient and has revealed a
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005, accepted March 1, 2005.ubgroup of individuals who display elevated BP in clinical
cenarios (i.e., “casual” BP) but normal ambulatory BP. The
erm “white-coat” hypertension (WCHT) has been used to
escribe this phenomenon (3). Another subgroup has re-
ently gained attention that comprises individuals with
levated ambulatory BP but normal casual BP. Pickering et
l. (4) named this trait “masked” hypertension (MHT). Two
ross-sectional studies have shown a higher prevalence of
arget organ damage in MHT groups (5,6). A cohort of an
nusual population (all exactly 70-year-old men, without
ajor cardiovascular complications and without antihyper-
ensive medication) has suggested a poor prognosis for
HT detected by ambulatory BP monitoring compared
ith normotensive subjects (7). However, the applicability
f this finding to the general population remains unclear.
Several longitudinal studies have investigated the prog-
ostic significance of WCHT as detected by ambulatory BP
onitoring (8–13). Although three of the studies used
ontrol subjects with normal BP (8,11,13), these were
olunteer subjects and thus did not comprise a representa-
ive sample. Results were ambiguous: two studies with mean
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August 2, 2005:508–15 Prognosis of Masked Hypertensionollow-up periods of less than five years showed similarly
ow cardiovascular risks in WCHT and normotensive con-
rol patients (8,11), but one study with a longer follow-up of
0 years demonstrated a higher risk compared with normo-
ensive control patients (13). Thus, the question of the
ong-term prognosis of WCHT remains unanswered.
We initiated ambulatory BP monitoring in a representa-
ive sample of men and women in a Japanese community
14) and have since been monitoring survival status and
troke occurrence (15,16). The present longitudinal study
ompared risks in subjects with WCHT, MHT, sustained
ypertension (SHT), and sustained normal blood pressure
SNBP) in this representative cohort of a general popula-
ion, including a broad range of subgroups, using data from
10-year follow-up.
ETHODS
esign. This report was based on longitudinal observations
f subjects who have been participating in an ambulatory BP
easurement project in Ohasama, Iwate Prefecture, Japan,
ince 1987. Socioeconomic and demographic characteristics
f this region and details of the study project have been
escribed previously (14–16). All study protocols were
pproved by the Institutional Review Board of Tohoku
niversity School of Medicine and by the Department of
ealth of the Ohasama town government.
tudy cohort. Selection of study subjects has been de-
cribed previously (15). Of the 2,716 residents of Ohasama
ho were 40 years of age, 575 were excluded because they
orked outside of town. This exclusion criterion was nec-
ssary because public health nurses visited subjects to attach
mbulatory BP monitoring devices during workdays. Indi-
iduals who were in hospital (n  121) or who were
uffering dementia or bedridden (n  31) also were ex-
luded. Of the remaining 1,989 eligible residents, 1,542
rovided informed consent and participated in the study.
asual BP measurements were not obtained from 210
ndividuals who did not participate in annual health check-
ps; therefore, the study cohort comprised 1,332 people,
epresenting 67% of the total eligible population. Mean age
as 61.0 years, and the male:female ratio was 40:60. The
epresentative nature of the study cohort has been fully
eported elsewhere (15).
mbulatory BP monitoring. Well-trained public health
Abbreviations and Acronyms
BP  blood pressure
CI  confidence interval
MHT  masked hypertension
RH  relative hazard
SHT  sustained hypertension
SNBP  sustained normal blood pressure
TIA  transient ischemic attack
WCHT  white-coat hypertensionurses visited participants on a weekday morning to attach ohe ambulatory BP monitoring device and returned to
etach it the next morning. Participants were asked to keep
diary in which they recorded daily activities, including
imes at which they went to bed and got up. Ambulatory BP
ata were included in the analysis if the monitoring period
ncluded more than 8 h of time spent during the waking
eriod (daytime) and more than 4 h during which the
ubject was in bed (nighttime). These periods were esti-
ated from subject diaries. Artifactual readings during
mbulatory BP monitoring were defined according to pre-
iously described criteria (17) and were omitted from
nalysis. Mean 24-h, daytime, and nighttime values for
mbulatory BP were calculated for each subject.
asual BP measurements. BP was measured twice by
urses or technicians at local medical centers using an
utomatic device with subjects in a seated position after
esting for at least 2 min. Casual BP was defined as the
ean of the two readings.
P monitoring device. Ambulatory BP was monitored
sing a fully automatic ABPM-630 device (Nippon Colin,
omaki, Japan) (18) preset to measure BP every 30 min.
lthough systolic and diastolic BP were measured using
oth cuff-oscillometric and microphone methods, only data
btained by the cuff-oscillometric method was used for
nalysis. Casual BP was measured using an automatic
SM-700F device (UEDA Electronic Works, Tokyo, Ja-
an) based on the Korotkoff sound technique (microphone
ethod). Devices used to measure ambulatory and casual
P have been previously validated (18,19) and meet all
riteria of the Association for the Advancement of Medical
nstrumentation (AAMI) (20). The device used to measure
asual BP also was calibrated annually by the Department of
ealth in Ohasama.
lassification of subjects. Subjects were classified into
our groups on the basis of daytime ambulatory BP and
asual BP levels: 1) SNBP (n 739, 55%), displaying casual
P140/90 mm Hg and daytime ambulatory BP135/85
m Hg; 2) WCHT (n  170, 13%), displaying casual BP
140/90 mm Hg and ambulatory BP 135/85 mm Hg; 3)
HT (n  221, 17%), displaying casual BP 140/90 mm
g and ambulatory BP 135/85 mm Hg; and 4) SHT (n
202, 15%), displaying casual BP 140/90 mm Hg and
mbulatory BP 135/85 mm Hg. Cut-off values were
erived from several guidelines (21–24). In the present
nalysis, subjects with SNBP included untreated subjects
ith “SNBP” and treated subjects with “controlled SNBP.”
he WCHT group included treated subjects with uncon-
rolled BP status only under medical settings. Similarly, the
HT group included those with “masked uncontrolled
ypertension” that would represent uncontrolled BP status
masked” by the use of casual BP measurement alone. These
oncepts are consistent with those used in a previous study
25) and are based on previous reports showing that an
nsufficient duration of action for antihypertensive drugs
epresents an important factor in causing higher ambulatory
r home BP values compared with casual BP (26).
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Prognosis of Masked Hypertension August 2, 2005:508–15ollow-up and outcomes. The residence of patients in
hasama as of December 31, 2001, was confirmed using
esidents’ registration cards, which are considered accurate
nd reliable, as they are the basis for pension and social
ecurity benefits in Japan. Causes of death by December 31,
001, were investigated with reference to the national
ortality registry, in which underlying cause of death was
lassified by death certificate according to the recommen-
ations of the International Classification of Diseases-
enth Revision (ICD-10). Primary outcome was deter-
ined as the composite of cardiovascular mortality and
troke morbidity. Secondary outcomes comprised: 1) car-
iovascular mortality and 2) stroke morbidity. Cardiovascu-
ar mortality was defined as death from diseases of the
irculatory system (ICD-10 code “I”). Incidence of stroke
nd transient ischemic attack (TIA) by December 31, 2001,
as investigated with reference to the Stroke Registration
ystem of Iwate Prefecture, national mortality registry,
ational Health Insurance receipts, and questionnaires sent
o each household at the time of ambulatory BP monitoring.
esults were then confirmed by checking the medical
ecords of Ohasama Hospital, which is the only hospital in
he town and is where 90% of patients undergo regular
heck-ups. Death certificates comprised the sole source of
nformation for only 2% of stroke cases. Most cases were
dmitted to Ohasama Hospital, where diagnosis was con-
rmed by computed tomography or magnetic resonance
maging of the brain. Diagnostic criteria for stroke and
troke subtypes were based on the Classification of Cere-
rovascular Disease 3 by the National Institute of Neuro-
ogical Disorders and Stroke (27).
ata analysis. Associations between each BP category and
utcome risks were examined using the Cox proportional
azard regression model (28). In all Cox analyses, the SNBP
roup was treated as the reference category. Among partic-
pants who experienced more than one outcome event
uring follow-up, survival time to the first relevant event
as used in each analysis. If a participant experienced more
han one type of outcome event during follow-up, each
vent contributed to the relevant outcome analysis, but only
he first event for any individual contributed to the com-
ined outcome analysis (stroke morbidity or cardiovascular
ortality). For example, if a participant experienced a
onfatal stroke on December 12, 1998, and then died from
oronary heart disease on February 7, 2001, the time from
aseline to December 12, 1998, was used as the survival
ime for stroke morbidity analysis and for combined out-
ome, whereas time from baseline to February 7, 2001, was
sed as the survival time for analysis of cardiovascular
ortality. Participants who died from other causes or who
ere lost to follow-up were treated as censored. In Cox
nalyses, age; gender; smoking status; use of antihyperten-
ive medications; and history of cardiovascular disease,
ypercholesterolemia, or diabetes mellitus were included as
ossible confounding variables in multivariate models.
Three subgroup analyses were conducted for the compos- gte outcome of cardiovascular mortality and stroke morbid-
ty: 1) comparison of risks in BP category between men and
omen; 2) comparison of risks in BP category between
ubjects with and without antihypertensive medications; and
) comparison of risks in BP category among subjects
lassified as low risk (no history of cardiovascular disease or
iabetes, and no risk factors), middle risk (no history of
ardiovascular disease or diabetes, but one to two risk
actors), or high risk (history of cardiovascular disease or
iabetes or three risk factors). Risk factors comprised: age
55 years for men; age 65 years for women; ever smoker;
nd hypercholesterolemia. Information on smoking status;
se of antihypertensive medications at baseline; and history
f heart disease, diabetes mellitus, or hypercholesterolemia
as obtained from questionnaires sent to each household at
he time of ambulatory BP measurements and from medical
ecords at Ohasama Hospital. Subjects who were adminis-
ered lipid-lowering drugs or who had serum cholesterol
evels of5.68 mmol/l (220 mg/dl) were considered to have
ypercholesterolemia. Subjects with a fasting glucose level
f 77 mmol/l (140 mg/dl) or nonfasting glucose level of
11.11 mmol/l (200 mg/dl) or who used insulin or oral
ntihyperglycemic drugs were defined as having diabetes
ellitus.
Estimated relative hazards (RHs) and 95% confidence
ntervals (CIs) for variables were derived from the coefficient
nd standard error of the mean as determined using the Cox
roportional hazards regression model (28). Homogeneity
etween subgroups was tested by adding interaction terms
o the relevant Cox models. Data are shown as (mean [SD]).
alues of p  0.05 were accepted as statistically significant.
ll statistical analyses were conducted using SAS version
.2 software (SAS Institute, Cary, North Carolina).
ESULTS
aseline characteristics. Mean ambulatory systolic BP
123.3 [13.0] mm Hg) and diastolic BP (72.0 [7.7] mm Hg)
ere significantly lower than casual systolic BP (131.2
18.5] mm Hg) and diastolic BP (74.1 [11.3] mm Hg). Of
he 1,332 study subjects, 272 (20%) were classified as
urrent or ex-smokers, and 405 (30%) were using antihy-
ertensive medications at baseline. A history of cardiovas-
ular disease, diabetes mellitus, or hypercholesterolemia was
resent in 75 (6%), 232 (17%), and 217 subjects (16%),
espectively.
Table 1 shows subject characteristics in each group. The
CHT and MHT groups displayed similar ages, gender
atios, and proportions of other risk factors. The SHT
roup was older and included a higher proportion of men,
mokers, and hypercholesterolemic subjects compared with
he WCHT and MHT groups. The SNBP group displayed
ower proportions of risk factors compared with the other
roups. Casual systolic/diastolic BP was significantly higher
n the WCHT group (152/82 mm Hg) than in the MHT
roup (127/73 mm Hg), whereas 24-h ambulatory systolic/
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August 2, 2005:508–15 Prognosis of Masked Hypertensioniastolic BP was significantly lower in the WCHT group
120/70 mm Hg) than in the MHT group (136/79 mm
g). Similar tendencies were observed for daytime and
ighttime ambulatory BP.
ollow-up and outcomes. Mean duration of follow-up
as 10.2 (2.7) years. A total of 26 subjects (2%) moved away
nd were lost to follow-up, whereas 67 cardiovascular deaths
5%) and 124 noncardiovascular deaths (9%) were recorded.
he number of deaths was somewhat increased compared
ith the number during the pilot phase based on a five-year
ollow-up (37 cardiovascular deaths, 56 noncardiovascular
eaths) (15). Of the cardiovascular deaths, 35 (52%) were
ue to stroke and 32 (48%) were due to heart disease. Of the
2 deaths due to heart disease, 12 were due to coronary
eart disease (myocardial infarction, n  9; angina pectoris,
 3), whereas the remaining were due to congestive heart
ailure (n 7), arrhythmia (n 3), and other heart diseases
able 1. Baseline Characteristics
Sustained
Normal BP
(n  739)
Wh
Hyp
(n
ge (yrs) 60 (10)
ale (%) 30
asual BP (mm Hg)
Systolic 121 (12) 1
Diastolic 70 (9)
mbulatory BP (mm Hg)
24-h
Systolic 116 (8) 1
Diastolic 68 (5)
Daytime
Systolic 121 (8) 1
Diastolic 72 (6)
Nighttime
Systolic 106 (10) 1
Diastolic 61 (6)
ntihypertensive treatment (%) 21
urrent or ex-smoker (%) 19
istory of cardiovascular disease (%) 4
istory of hypercholesterolemia (%) 14
istory of diabetes (%) 15
ontinuous values are shown as mean (SD).
BP  blood pressure.
igure 1. Relative hazards (RH) and 95% confidence intervals (CI) of sustai
ypertension (MHT), and sustained hypertension (SHT) for cardiovascular d
ortality/stroke morbidity. Numbers inside bars indicate 95% CI. The SNBPn  10), respectively. Stroke or TIA occurred in 112
ubjects (8%), because of cerebral infarction in 75 (67%),
ntracerebral hemorrhage in 23 (21%), subarachnoid hem-
rrhage in 10 (9%), TIA in 3 (3%), and unknown causes in
(1%). Of the 112 subjects who experienced stroke or TIA,
7 (24%: 23 due to stroke, 4 due to heart disease) died
uring the follow-up period. Composite cardiovascular
ortality and stroke morbidity thus comprised 152 events.
Figure 1 shows risk of primary and secondary outcomes in
ach group. RH for the composite events was significantly
igher in the SHT (RH  2.26, p  0.0001) and MHT
roups (RH  2.13, p  0.0006) compared with the SNBP
roup, whereas no difference was identified with the
CHT group (RH  1.28, p  0.4). Similar relationships
ere observed for risk of cardiovascular mortality and stroke
orbidity (Fig. 1). Further adjustment for casual systolic
nd diastolic BP levels did not change the increased risk in
oat
sion
0)
Masked
Hypertension
(n  221)
Sustained
Hypertension
(n  202) p Value
) 63 (9) 66 (10) 0.001
36 47 0.001
2) 127 (9) 155 (15) 0.001
2) 73 (9) 86 (11) 0.001
) 136 (8) 140 (10) 0.001
) 79 (6) 81 (7) 0.001
) 143 (8) 147 (9) 0.001
) 84 (6) 86 (7) 0.001
1) 122 (13) 127 (14) 0.001
) 70 (8) 71 (8) 0.001
34 48 0.001
22 26 0.2
6 7 0.06
20 18 0.02
19 22 0.01
ormal blood pressure (SNBP), white-coat hypertension (WCHT), maskedite-C
erten
 17
64 (9
38
52 (1
82 (1
20 (7
70 (5
25 (7
74 (6
11 (1
63 (7
45
19
9
21
19ned n
isease (CVD) mortality, stroke morbidity, and the composite of CVD
group was treated as the reference category.
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Prognosis of Masked Hypertension August 2, 2005:508–15he MHT group: RHs (95% CI) in the MHT group
ompared with the SNBP group for cardiovascular mortal-
ty, stroke morbidity, and composite events were 1.88 (0.94
o 3.74), 2.13 (1.28 to 3.56), and 2.01 (1.30 to 3.11),
espectively. In a multivariate Cox model with continuous
P variables, ambulatory BP parameters represented a
ignificant predictor of cardiovascular outcomes, whereas
asual BP did not represent a significant predictor after
imultaneous adjustment for ambulatory BP parameters
Table 2).
ubgroup analyses. Similar relationships were observed
mong men and women (Fig. 2); among subjects with and
ithout antihypertensive medications (Fig. 3); and among
ubjects classified as low, middle, or high risk (Fig. 4) for
able 2. RH and 95% CIs With a BP Increase of 10 mm Hg fo
ortality/Stroke Morbidity
Models* CVD Mortality
BP Variables RH (95% CI) p Value
ystolic BP
Casual  24 h
Casual 1.04 (0.91–1.19) 0.5
24-h 1.27 (1.04–1.55) 0.02
Casual  daytime
Casual 1.06 (0.93–1.21) 0.4
Daytime 1.17 (0.97–1.41) 0.1
Casual  nighttime
Casual 1.05 (0.92–1.20) 0.5
Nighttime 1.33 (1.11–1.58) 0.002
iastolic BP
Casual  24 h
Casual 1.00 (0.80–1.25) 0.9
24-h 1.27 (0.89–1.80) 0.2
Casual  daytime
Casual 1.02 (0.81–1.27) 0.9
Daytime 1.14 (0.83–1.58) 0.4
Casual  nighttime
Casual 0.99 (0.80–1.23) 0.9
Nighttime 1.45 (1.05–1.99) 0.02
All models were adjusted for age, gender, smoking status, use of antihypertensive me
nd simultaneously adjusted for each BP value.
BP  blood pressure; CI  confidence interval; CVD  cardiovascular disease;
igure 2. Relative hazards (RH) and 95% confidence intervals (CI) of sustai
ypertension (MHT), and sustained hypertension (SHT) for risk of the compos
umbers inside bars indicate 95% CI. The SNBP group was treated as the reisk of composite outcomes. No significant interactions were
bserved for risk among the aforementioned subgroups (p
or interaction 0.2 for all).
ISCUSSION
his study was based on a 10-year observation of a represen-
ative sample of the general population in Japan. We demon-
trated that risk of cardiovascular mortality and stroke morbid-
ty in subjects with MHT or SHT was significantly higher
han risk in subjects with SNBP, whereas the risk in subjects
ith WCHT did not differ from that for subjects with SNBP.
mportantly, these relationships were observed among a broad
ange of subgroups without significant heterogeneity. To the
D Mortality, Stroke Morbidity, and the Composite of CVD
Stroke CVD Mortality/Stroke
(95% CI) p Value RH (95% CI) p Value
(0.94–1.15) 0.3 1.05 (0.96–1.15) 0.3
(1.21–1.62) 0.0001 1.33 (1.17–1.51) 0.0001
(0.93–1.15) 0.4 1.05 (0.96–1.15) 0.3
(1.19–1.57) 0.0001 1.27 (1.12–1.43) 0.0001
(0.98–1.19) 0.09 1.07 (0.99–1.17) 0.1
(1.10–1.43) 0.0001 1.26 (1.13–1.41) 0.0001
(0.90–1.27) 0.4 1.05 (0.91–1.22) 0.5
(1.35–2.21) 0.0001 1.54 (1.24–1.92) 0.0001
(0.90–1.26) 0.4 1.06 (0.91–1.23) 0.4
(1.33–2.10) 0.0001 1.43 (1.17–1.75) 0.0005
(0.96–1.34) 0.1 1.08 (0.94–1.25) 0.3
(1.16–1.85) 0.0001 1.47 (1.20–1.80) 0.0002
ons, and history of cardiovascular disease, hypercholesterolemia, or diabetes mellitus,
relative hazard.
ormal blood pressure (SNBP), white-coat hypertension (WCHT), maskedr CV
RH
1.04
1.40
1.03
1.37
1.08
1.26
1.07
1.73
1.06
1.67
1.14
1.46
dicatined n
ite of cardiovascular disease (CVD) mortality/stroke morbidity by gender.
ference category.
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August 2, 2005:508–15 Prognosis of Masked Hypertensionest of our knowledge, this is the first prospective study to
eveal the risks associated with WCHT and MHT in a
epresentative sample of the general population.
rognostic significance of MHT. One smaller cohort
tudy has reported poor prognosis in MHT detected by
mbulatory BP monitoring compared with normotensive
ubjects (7). However, study subjects were limited to un-
reated men who were exactly 70 years of age with no history
f cardiovascular disease, and WCHT was excluded from
nalysis. The present study is the first to report that MHT
s related to increased cardiovascular risk among women and
reated subjects, irrespective of the number of risk factors or
ardiovascular complications. Importantly, even among sub-
ects with a low cardiovascular risk profile, MHT is associ-
ted with a significantly greater risk of stroke and cardio-
ascular mortality. These results are consistent with a recent
rospective study of hypertensive patients receiving antihy-
ertensive medication, which showed that masked uncon-
rolled hypertension as detected by self-measured BP at
ome is associated with increased risk of cardiovascular
igure 3. Relative hazards (RH) and 95% confidence intervals (CI) of sustai
ypertension (MHT), and sustained hypertension (SHT) for risk of the c
ntihypertensive treatment. Treated subjects, subjects treated using a
ntihypertensive medication. Numbers inside bars indicate 95% CI. The
igure 4. Relative hazards (RH) and 95% confidence intervals (CI) of sustai
ypertension (MHT), and sustained hypertension (SHT) for risk of the c
isk profile. Low-risk group, patients without history of CVD or diabetes
r diabetes but with one to two risk factors; High-risk group, patients with his
ndicate 95% CI. The SNBP group was treated as the reference category.vents compared with sustained controlled hypertension
25). These results support the concept that BP measure-
ents outside the clinical setting offer stronger predictive
ower for cardiovascular disease than casual BP (29) because
his method allows multiple BP measurements outside the
ospital, subtly reflects duration of action of antihyperten-
ive drugs (26), is free of observer bias and the white-coat
ffect, and provides more reproducible information than
asual BP measurements (1,2), although reproducibility of
he condition of MHT remains to be investigated.
rognostic significance of WCHT. The present results
re consistent with some previous studies in that WCHT
as associated with a more benign outcome than SHT
8–12). This is the first report to compare risk in WCHT
ith representative subjects displaying SNBP, and we
howed that risk in WCHT does not differ significantly
rom that in SNBP after follow-up for 10 years. These
esults are again consistent with some previous smaller and
horter studies (8,11). However, given the 95% CI (0.76 to
.14), small- to moderate-sized increases in risk remain
ormal blood pressure (SNBP), white-coat hypertension (WCHT), masked
site of cardiovascular disease (CVD) mortality/stroke morbidity by use of
ertensive medication; Untreated subjects, subjects not treated using
P group was treated as the reference category.
ormal blood pressure (SNBP), white-coat hypertension (WCHT), masked
site of cardiovascular disease (CVD) mortality/stroke morbidity by CVD
ith no risk factors; Middle-risk group, patients without history of CVDned n
ompo
ntihypned n
ompo
and wtory of CVD or diabetes or with three risk factors. Numbers inside bars
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rospective study (13) and some cross-sectional studies
6,30–32) have reported that WCHT could be associated
ith more advanced cardiovascular target organ damage
ompared with normotensive subjects. Thus, WCHT re-
ains a condition warranting careful follow-up.
tudy limitations. In this study, BPs measured at the
eginning of the follow-up period were used because the
bjective of the study was to examine the risk of MHT and
CHT as defined according to initial baseline BP.
hether the results might differ for patients classified into
ubgroups according to levels obtained during follow-up
emains yet to be investigated, particularly with regard to
reated patients, because BP levels achieved by treatment
ffer the most relevant prognostic information (33).
In our study, two BP readings from a single visit were
veraged for use as a measure of casual BP. In contrast,
asual BP calculated on the basis of six readings (two
eadings from each of three visits) demonstrated that
orrelations between left ventricular mass and either casual
r ambulatory BP became much stronger when readings
ere averaged over more than one visit (34). Future studies
eed to test whether the present findings will remain
pplicable when MHT and WCHT are defined according
o repeated casual readings.
Casual and ambulatory BPs were measured using two
ifferent technical approaches in our study. However, mean
ifferences in BP measurements between the auscultatory
ethod and those using other devices were small (35), and
ll BP measuring devices have been validated formally
ccording to the AAMI (20). These methods are thus
nlikely to have resulted in misclassification of BP. In
ddition, marked differences exist in the epidemiologies of
ardiovascular disease between Japan and the U.S. or Eu-
opean countries. Among Japanese, coronary artery disease
s much less common, whereas stroke is more common than
mong white or black populations. Further research in other
thnic and cultural populations is needed to confirm the
eneralizability of our findings.
linical implications and conclusions. Masked hyperten-
ion represents a strong predictor of cardiovascular risk and
as present in 16% of subjects without antihypertensive
edication and 18% of those with antihypertensive medi-
ation. Our results thus suggest that 16 truly high-risk
ubjects of every 100 persons without antihypertensive
edication may not be identified under conventional casual
P measurements but could be detected using ambulatory
P measurements, whereas 18 truly uncontrolled patients
ut of every 100 patients under antihypertensive medication
ay not be identified under casual BP measurements but
ould be detected using ambulatory BP measurements.
nless individuals with MHT are identified, they will
emain untreated or inadequately controlled and might
xperience cardiovascular complications and target organ
amage, with poor quality of life the eventual result.
nnecessary medical costs also will be incurred. This in turnuggests the possibility that detection and management of
ypertension based on ambulatory BP could improve prog-
osis for at-risk populations. However, direct evidence from
andomized controlled trials comparing ambulatory and
asual BP-based management of hypertension on risk of
ardiovascular outcomes is necessary to truly elucidate the
linical significance of ambulatory BP monitoring.
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